Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)

This grant opportunity (PAR-25-069) from the NIH seeks research proposals to investigate the mechanisms by which incretin mimetics impact cancer risk. The funding is available through CFDA 93.393 and supports R01 clinical trials (optional).